The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy.Published in:Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1532104By:Guo, Huihui;Xie, Hongsheng;Huang, Yuanyuan;Jia, Junxiang;Kong, Xiangfei;Yang, Qingliang;Gai, Shun;Li, Wenjun;Bai, Lu;Zhang, Lingli;Chen, Xiaoxiao;Ye, Zhicang;Ye, Hangbo;Zhao, Linyao;Xu, Yifang;Du, Yong;Zhang, Xiuzhen;Chen, Miaomiao;Zhou, Xiaomai;Zhao, Robert Y.Publication type:Article